Position in HLN
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$9,837,897
+$5,623,177 QoQ
Shares Held
1,054,437
+150.4% QoQ
Ownership
0.024%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
#51
of 639 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in HLN Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026CAPITAL FUND MANAGEMENT S.A. holds $95,675,665 across 11 Drug Manufacturers - Specialty & Generic names. HLN ranks #5 (10.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | UTHR |
UNITED THERAPEUTICS Corp
|
53,037 | $28,737,037 | |
| 2 | HIMS |
Hims & Hers Health, Inc.
|
568,912 | $19,724,179 | |
| 3 | NBIX |
Neurocrine Biosciences Inc
|
98,117 | $16,536,639 | |
| 4 | ZTS |
Zoetis Inc.
|
150,407 | $10,808,247 | |
| 5 | HLN |
Haleon plc
This page
|
1,054,437 | $9,837,897 | |
| 6 | SUPN |
Supernus Pharmaceuticals, Inc.
|
73,219 | $3,405,415 | |
| 7 | ALKS |
Alkermes plc.
|
33,281 | $1,743,924 | |
| 8 | LQDA |
Liquidia Corp
|
20,491 | $1,633,747 |
All Filings in HLN
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $9,837,897 | 1,054,437 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $4,214,720 | 421,051 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $5,792,463 | 572,944 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $7,147,681 | 796,843 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $5,713,745 | 550,988 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $1,119,840 | 108,828 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $519,176 | 54,421 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $2,361,456 | 223,200 | Shares | Sole | 2024-11-13 | |
| No filing history on record for this holder in this stock. | ||||||